Prochymal® Clinical Trials for the Treatment of Acute GvHD

Acute graft versus host disease (GvHD) is a potentially life threatening complication that arises in approximately 50% of all patients who receive a hematopoietic stem cell transplant (HSCT). Allogeneic HSCT are used for the treatment of diseases including hematological malignancies, certain forms of anemia, and immunological deficiencies. The transplant is derived from donated bone marrow, cord blood, or peripheral blood. GvHD occurs when immune cells in the donated cell population attack the recipient cells because the recipient cells are seen as “foreign.” Organs that are mainly affected by the immunological attack are the gastrointestinal (GI) tract, skin, and liver.


Phase 3 steroid refractory acute GvHD trial - Patient enrollment is complete.
Phase 3 newly diagnosed acute GvHD trial - Patient enrollment is complete.
Pediatric Expanded Access Program - Patients are being accepted.

Osiris Therapeutics, Inc. • 7015 Albert Einstein Drive • Columbia, MD • 21046 • p(443) 545-1800 • osiris@osiris.comLegal Notice